Bipolar Treatment

Bipolar treatment goes wrong in the first appointment more often than in any later one. Get the diagnosis wrong and every prescription after it is wrong. And bipolar gets missed both ways. Plenty of people who genuinely have bipolar II spend a decade on antidepressants for what looks like depression that keeps coming back. Plenty of other people who are just moody, hung over, sleep-wrecked, or trauma-reactive get told they have bipolar and started on lithium for the rest of their lives when they don’t need it. The first appointment is the most expensive one in the whole arc, and most of the field treats it like a triage step instead of a diagnostic step.

The Hollywood version of bipolar is somebody awake for four days, spending the rent on a sports car, flying to Vegas to start a band. That’s bipolar I in a full manic episode, it’s real, and it’s the loud edge of a much wider category. Most of what walks into the field’s offices is way quieter. A guy who’s spent three weeks barely getting out of bed, then a week or two of feeling weirdly productive on three hours of sleep a night, who doesn’t quite connect the two states because the productive part felt like finally being normal for a change.

Bipolar I, II, and cyclothymia are different illnesses sharing a last name

Bipolar I requires at least one full manic episode. Manic, not energetic. A week or more (or any duration if it landed you in a hospital) where the mood is jacked up or irritable, the sleep dropped to a few hours and you don’t miss it, the thoughts are racing, the speech is pressured, the spending or the cheating or the new business idea is genuinely out of character… sometimes psychosis on top. The depressions in bipolar I exist and they’re brutal, but it’s the manias that make it bipolar I.

Bipolar II is the one that gets missed and missed and missed. The high side is hypomania, which is the same cluster of stuff at lower volume and shorter duration… four days or more of the elevated mood and sleep loss and racing thoughts, without psychosis, without anyone calling 911. The depressions, on the other hand, are usually long and heavy. Patients walk in describing the depressions, the hypomanias get filed in their memory as “the good weeks when I finally got my shit together,” and the prescriber writes an SSRI. Sometimes that flips them into a mixed state and now you’ve got a real problem.

Lithium is still the gold standard, and the way that sounds in your head, “old drug, surely we’ve moved past it,” is wrong.

Cyclothymia is the long, low-grade version. Two years or more of the mood sliding around between sub-threshold hypomanic and sub-threshold depressive symptoms, never quite hitting full episodes, never really stable either. People with cyclothymia often spend years convinced their personality is the problem because nothing dramatic ever quite happens… it just feels like everything is harder than it should be all the time. It responds to mood stabilizers the same way the bigger versions do, and treating it matters because cyclothymia frequently graduates into bipolar I or II if it’s left alone long enough.

Say you’ve got a guy who comes in already on his fourth SSRI, each one had worked for about three weeks and then either pooped out or made him “wired and weird,” and nobody before me had thought to ask about the wired-and-weird weeks. He wasn’t treatment-resistant depression. He was bipolar II with antidepressant-induced hypomania every single time somebody reached for the prescription pad. That’s the kind of miss the field cranks out by the dozen because nobody has time in a fifteen-minute med check to take a real history.

Mood stabilizers, ranked roughly by what works

Lithium is still the gold standard, and the way that sounds in your head, “old drug, surely we’ve moved past it,” is wrong. It’s been around since the 1950s, seventy years of data, and it’s still the only mood stabilizer with a clear signal for reducing suicide independent of the mood-stabilizing effect. Dosing usually lands between 600 and 1200 mg a day, titrated to a blood level somewhere between 0.6 and 1.0 mEq/L. The price of admission is monitoring. Lithium level, kidney function (creatinine), thyroid (TSH), every few months at first and then a couple of times a year for as long as you’re on it. The drug has a narrow therapeutic window, which means the line between “working” and “toxic” is closer than for most drugs, and that scares prescribers off it more than the drug itself deserves. Once you find the dose, most patients tolerate it remarkably well.

Valproate (Depakote) is the workhorse for acute mania and rapid-cycling stuff. Faster onset than lithium, less monitoring fuss day to day, worse long-term partner. Weight gain, hair thinning, occasional liver enzyme bumps, and absolutely off the table for anyone who could become pregnant unless you’ve had a long honest conversation about birth defect risk. The neural tube defect data on valproate is one of the clearer “don’t do this” signals in psychiatry.

Lamotrigine (Lamictal) is the one for the depressive side of bipolar II. Pretty quiet on the manic side, so it’s not a first pick for someone whose problem is mostly the highs, but for the bipolar II patient whose actual problem is the deep, long depressions, it’s often the cleanest option you’ve got. The catch is the titration. You start at 25 mg and creep up over six weeks because of a real rash risk (Stevens-Johnson syndrome, a serious skin reaction that can land you in a burn unit). Rush the titration and you can hurt someone, and patients hate the slow build because they want to feel something now… explain why the timeline matters or they’ll bail in week two.

Carbamazepine still has a niche for mixed states and folks who didn’t respond to anything above. The drug interactions are a nightmare because carbamazepine cranks up half the liver enzymes that metabolize everything else you’re on, so I reach for it third or fourth.

The atypicals filled a real gap, especially for bipolar depression

For a long time the depressed side of bipolar was a mess to treat. Mood stabilizers alone often weren’t enough, and antidepressants alone were risky. Then a handful of atypical antipsychotics (a newer class of antipsychotic medications, used at lower doses for mood issues than they’d be for actual psychosis) started accumulating real evidence specifically for bipolar depression, and the playbook moved.

Lurasidone (Latuda) has a clean FDA indication for bipolar depression and a reasonably friendly side effect profile. It has to be taken with at least 350 calories of food or it doesn’t absorb properly, which trips up about half of patients constantly. Quetiapine (Seroquel) is the older option in the same lane, it works, it’s also sedating and rough on weight and metabolic numbers over years. Caplyta (lumateperone) is the newer entry in the same category, works about as well as the older two with a friendlier profile on weight and on prolactin, and it’s earned a spot in the rotation for patients who couldn’t tolerate Latuda’s GI issues or quetiapine’s sedation.

None of these are substitutes for a mood stabilizer in bipolar I. They’re partners. Lithium plus an atypical is one of the more common stable long-term combos I write.

Stable on medication for ten years is a better life than four episodes and three hospitalizations off it. Most of bipolar treatment is getting the patient to accept that trade.

Antidepressants in bipolar are a controlled-handling problem

You can use them. Sometimes you have to. Putting a bipolar patient on an SSRI or SNRI without a mood stabilizer underneath is one of the most reliable ways to make things worse, though, the risk is induced mania, mixed states, or rapid cycling, and it doesn’t always show up immediately. People do fine for two months on bupropion and then arrive in the office in week ten not having slept in four days… that’s the version of this story I’ve watched more times than I’d like.

If an antidepressant is going on board, it goes on top of a mood stabilizer, at a lower dose than you’d use in unipolar depression, with somebody in the patient’s life who knows what to watch for. SNRIs and tricyclics are higher risk for the flip than SSRIs. The order matters… stabilizer first, antidepressant second, never the other way around.

Most of bipolar treatment is getting the patient to accept that trade.

Sleep, schedule, and the therapy that actually moves the needle

Bipolar is the diagnosis where lifestyle stuff stops being a wellness suggestion and becomes part of the prescription. Sleep deprivation is a known trigger for manic episodes. Shift work, jet lag, a new baby, finals week, any of it can flip a previously steady patient. The schedule itself, what time you wake up and eat and work and sleep, matters more here than for almost any other psychiatric condition.

That’s why IPSRT (interpersonal and social rhythm therapy, which is a specific structured therapy that treats your daily rhythm as a clinical variable, you log wake times and meal times and bedtimes and social contact, and over a few weeks the rhythm gets boring on purpose) was built. The data on IPSRT plus medication is solid enough that I bring it up with every newly diagnosed bipolar patient, even the ones who roll their eyes at the idea of charting their wake-up time on a piece of paper. Family-focused therapy matters more than people expect too, because the people living with a bipolar patient are usually the first to notice the early signs of an episode, weeks before the patient does.

What’s nice to hear about all this

Lead with the unpleasant stuff because that’s the default and reverse it now. The patients who actually settle into a regimen they can live with do really well. We’re not talking about white-knuckling through misery for the rest of your life. We’re talking about a mood that stops costing you jobs, a marriage that gets to keep being a marriage, the freedom to plan a vacation in six months and reasonably expect to still be the same guy when you get on the plane. Lithium plus a low-dose atypical, plus enough sleep, plus a couple years of practice noticing the early warning signs, and life starts looking pretty boring in the best possible way. The 90 percent of bipolar patients who eventually plateau into “stable, taking my meds, working, married, a little tired sometimes” is the part the field never advertises because boring doesn’t sell.

Where I land on the medication question, and where you land is yours

If you have bipolar I, lifelong medication is the right call essentially every time, and the math on it isn’t really negotiable in a way I’d feel ok backing. Manic episodes do damage that compounds. Each one makes the next one easier to fire off, and a few of them cost you a marriage or a license or a year of work you don’t get back. So with bipolar I, when patients ask if they have to be on something forever, the honest answer is yes, almost always.

For bipolar II and cyclothymia the conversation is real. Plenty of patients do well on medication, plenty of others end up trying to come off after some stable years and either holding the gains or sliding back, and either way the decision is theirs. I’m a provider, not a parent, my job is the honest take on what the data says about staying versus stopping, your job is what to do with that. The disapproving-yes happens here a lot… I’ll keep the script open while we taper if that’s what the patient wants, with a clear plan for what triggers a restart and who’s watching for it.

The patients who chase being cured tend to stop their meds during a good stretch and the stretch ends about six weeks later in some painful way, a job, a marriage, sometimes worse. The patients who accept that “stable” is the goal, that the cure isn’t coming, that the schedule is part of the prescription, do better than almost anything else psychiatry treats. Bipolar is one of the few diagnoses where the gap between treated and untreated is so big that it doesn’t really require selling.

Sources

1. Yatham LN, Kennedy SH, Parikh SV, et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) 2018 guidelines for the management of patients with bipolar disorder. Bipolar Disord. 2018;20(2):97-170. PMID 29536616.
2. Cipriani A, Hawton K, Stockton S, Geddes JR. Lithium in the prevention of suicide in mood disorders: updated systematic review and meta-analysis. BMJ. 2013;346:f3646. PMID 23814104.
3. Miklowitz DJ, Efthimiou O, Furukawa TA, et al. Adjunctive Psychotherapy for Bipolar Disorder: A Systematic Review and Component Network Meta-analysis. JAMA Psychiatry. 2021;78(2):141-150. PMID 33052390.
4. Hashimoto Y, Kotake K, Watanabe N, et al. Lamotrigine in the maintenance treatment of bipolar disorder. Cochrane Database Syst Rev. 2021;(9):CD013575. PMID 34523118.